Amphiregulin activates regulatory T lymphocytes and suppresses CD8+ T cell-mediated anti-tumor response in hepatocellular carcinoma cells

Oncotarget

Volumn 6, Issue 31, 2015, Pages 32138-32153

  Yuan, Chun Hui ^a   Sun, Xiao Ming ^b   Zhu, Cheng Liang ^b   Liu, Shao Ping ^a   Wu, Long ^c   Chen, Hao ^a   Feng, Mao Hui ^a   Wu, Ke ^b   Wang, Fu Bing ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Amphiregulin; CD4+ regulatory T cells; CD8+ T cells; Hepatocellular carcinoma

Indexed keywords

AMPHIREGULIN; GEFITINIB; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; NEUTRALIZING ANTIBODY; RAPAMYCIN; SMALL INTERFERING RNA; VASCULOTROPIN RECEPTOR; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AR GENE; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOLOGY; GENE EXPRESSION; GENE FUNCTION; HEPATOCELLULAR CARCINOMA CELL LINE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MALE; MOUSE; NONHUMAN; ONCOGENE; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNOLOGY; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL CULTURE; WESTERN BLOTTING;

AMPHIREGULIN; ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; LIVER NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; T-LYMPHOCYTES, REGULATORY; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945567593     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5171     Document Type: Article

References (53)

1. Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Sakai A, Sakai Y, et al. Comparative analysis of various tumorassociated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology. 2011; 53:1206-16.
2. Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP, et al. Spontaneous tumorspecific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res. 2004; 10:4332-41.
3. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003; 198:1875-86.
4. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10:942-9.
5. Wei S, Kryczek I, Zou W. Regulatory T-cell compartmentalization and trafficking. Blood. 2006; 108:426-31.
6. Kalathil S, Lugade AA, Miller A, Iyer R,Thanavala Y. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 2013; 73:2435-44.
7. Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007; 132:2328-39.
8. Zhao HQ, Li WM, Lu ZQ, Yao YM. Roles of Tregs in development of hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2014; 20:7971-8.
9. Sharma S, Khosla R, David P, Rastogi A, Vyas A, Singh D, et al. CD4+CD25+CD127(low) Regulatory T Cells Play Predominant Anti-Tumor Suppressive Role in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Front Immunol. 2015; 6:49.
10. Zaiss DM, van Loosdregt J, Gorlani A, Bekker CP, Grone A, Sibilia M, et al. Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity. 2013; 38:275-84.
11. Dai K, Huang L, Chen J, Yang L,Gong Z. Amphiregulin promotes the immunosuppressive activity of intrahepatic CD4 regulatory T cells to impair CD8 T cell immunity against hepatitis B virus infection. Immunology. 2014.
12. Busser B, Sancey L, Brambilla E, Coll JL, Hurbin A. The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta. 2011; 1816:119-31.
13. McBryan J, Howlin J, Napoletano S, Martin F. Amphiregulin: role in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia. 2008; 13:159-69.
14. Busser B, Coll AJL, Hurbin A. The increasing role of amphiregulin in non-small cell lung cancer. Pathol Biol (Paris). 2009; 57:511-2.
15. Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Donev IS, et al. The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer. Clin Cancer Res. 2011; 17:3619-30.
16. Latasa MU, Salis F, Urtasun R, Garcia-Irigoyen O, Elizalde M, Uriarte I, et al. Regulation of amphiregulin gene expression by beta-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system. PLoS One. 2012; 7:e52711.
17. Castillo J, Goni S, Latasa MU, Perugorria MJ, Calvo A, Muntane J, et al. Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in human hepatocellular tumors. Gastroenterology. 2009; 137:1805-15. e1-4.
18. Zhou J, Ding T, Pan W, Zhu LY, Li L,Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer. 2009; 125:1640-8.
19. Curry MP, Norris S, Golden-Mason L, Doherty DG, Deignan T, Collins C, et al. Isolation of lymphocytes from normal adult human liver suitable for phenotypic and functional characterization. J Immunol Methods. 2000; 242:21-31.
20. Liu M, Wilk SA, Wang A, Zhou L, Wang RH, Ogawa W, et al. Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. J Biol Chem. 2010; 285:36387-94.
21. Han SX, Bai E, Jin GH, He CC, Guo XJ, Wang LJ, et al. Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J Immunol Res. 2014; 2014:261365.
22. Miceli V, Cervello M, Azzolina A, Montalto G, Calabro M,Carruba G. Aromatase and amphiregulin are correspondingly expressed in human liver cancer cells. Ann N Y Acad Sci. 2009; 1155:252-6.
23. Kuramochi H, Nakajima G, Kaneko Y, Nakamura A, Inoue Y, Yamamoto M, et al. Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases. BMC Cancer. 2012; 12:88.
24. Yotsumoto F, Fukami T, Yagi H, Funakoshi A, YoshizatoT, Kuroki M, et al. Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. Cancer Sci. 2010; 101:2351-60.
25. Liu Q, Rehman H, Krishnasamy Y, Haque K, Schnellmann RG, Lemasters JJ, et al. Amphiregulin stimulates liver regeneration after small-for-size mouse liver transplantation. Am J Transplant. 2012; 12:2052-61.
26. Zhu J, Siclari VA, Liu F, Spatz JM, Chandra A, Divieti Pajevic P, et al. Amphiregulin-EGFR signaling mediates the migration of bone marrow mesenchymal progenitors toward PTH-stimulated osteoblasts and osteocytes. PLoS One. 2012; 7:e50099.
27. Zeng H, Yang K, Cloer C, Neale G, Vogel P,Chi H. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature. 2013; 499:485-90.
28. Wang Y, Camirand G, Lin Y, Froicu M, Deng S, Shlomchik WD, et al. Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice. J Immunol. 2011; 186:2809-18.
29. Schmidt N, Neumann-Haefelin C,Thimme R. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy. Dig Dis. 2012; 30:483-91.
30. Zhang HH, Mei MH, Fei R, Liao WJ, Wang XY, Qin LL, et al. Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro. Int J Oncol. 2010; 36:841-8.
31. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res. 2007; 13:902-11.
32. Thorne BA,Plowman GD. The heparin-binding domain of amphiregulin necessitates the precursor pro-region for growth factor secretion. Mol Cell Biol. 1994; 14:1635-46.
33. Okumura S, Sagara H, Fukuda T, Saito H, Okayama Y. FcepsilonRI-mediated amphiregulin production by human mast cells increases mucin gene expression in epithelial cells. J Allergy Clin Immunol. 2005; 115:272-9.
34. Qi Y, Operario DJ, Oberholzer CM, Kobie JJ, Looney RJ, Georas SN, et al. Human basophils express amphiregulin in response to T cell-derived IL-3. J Allergy Clin Immunol. 2010; 126:1260-6. e4.
35. Hsu YL, Huang MS, Cheng DE, Hung JY, Yang CJ, Chou SH, et al. Lung tumor-associated dendritic cellderived amphiregulin increased cancer progression. J Immunol. 2011; 187:1733-44.
36. Wills-Karp MF, Finkelman D. Innate lymphoid cells wield a double-edged sword. Nat Immunol. 2011; 12:1025-7.
37. Piepkorn M, Underwood RA, Henneman C, Smith LT. Expression of amphiregulin is regulated in cultured human keratinocytes and in developing fetal skin. J Invest Dermatol. 1995; 105:802-9.
38. Zaiss DM, Yang L, Shah PR, Kobie JJ, Urban JF, Mosmann TR. Amphiregulin, a TH2 cytokine enhancing resistance to nematodes. Science. 2006; 314:1746.
39. Martinez-Lacaci I, Saceda M, Plowman GD, Johnson GR, Normanno N, Salomon DS, et al. Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines. Endocrinology. 1995; 136:3983-92.
40. Mahtouk K, Hose D, Reme T, De Vos J, Jourdan M, Moreaux J, et al. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene. 2005; 24:3512-24.
41. Busser B, Sancey L, Brambilla E, Coll JL, Hurbin A. The multiple roles of amphiregulin in human cancer. Biochimica Et Biophysica Acta-Reviews on Cancer. 2011; 1816:119-131.
42. Berasain C, Castillo J, Perugorria MJ, Prieto J,Avila MA. Amphiregulin: A new growth factor in hepatocarcinogenesis. Cancer Letters. 2007; 254:30-41.
43. Berasain C, Garcia-Trevijano ER, Castillo J, Erroba E, Lee DC, Prieto J, et al. Amphiregulin: an early trigger of liver regeneration in mice. Gastroenterology. 2005; 128:424-32.
44. Berasain C, Garcia-Trevijano ER, Castillo J, Erroba E, Santamaria M, Lee DC, et al. Novel role for amphiregulin in protection from liver injury. J Biol Chem. 2005; 280:19012-20.
45. Murthy A, Defamie V, Smookler DS, Di Grappa MA, Horiuchi K, Federici M, et al. Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice. J Clin Invest. 2010; 120:2731-44.
46. Castillo J, Erroba E, Perugorria MJ, Santamaria M, Lee DC, Prieto J, et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Research. 2006; 66:6129-6138.
47. Latasa MU, Salis F, Urtasun R, Garcia-Irigoyen O, Elizalde M, Uriarte I, et al. Regulation of Amphiregulin Gene Expression by beta-Catenin Signaling in Human Hepatocellular Carcinoma Cells: A Novel Crosstalk between FGF19 and the EGFR System. Plos One. 2012; 7.
48. Alatrakchi N,Koziel M. Regulatory T cells and viral liver disease. J Viral Hepat. 2009; 16:223-9.
49. Stross L, Gunther J, Gasteiger G, Asen T, Graf S, Aichler M, et al. Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice. Hepatology. 2012; 56:873-83.
50. Sun AM, Li CG, Zhang YQ, Lin SM, Niu HR,Shi YS. Hepatocarcinoma cell-derived hepatoma-derived growth factor (HDGF) induces regulatory T cells. Cytokine. 2015; 72:31-35.
51. Berasain C, Ujue Latasa M, Urtasun R, Goni S, Elizalde M, Garcia-Irigoyen O, et al. Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers (Basel). 2011; 3:2444-61.
52. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149:274-93.
53. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity. 2009; 30:832-44.